A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With AdvancedMetastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Inclusion Criteria:

• Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC
• Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3, VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2, or FGFR3 activating mutation
• Availability of tumor tissue sample suitable for the central confirmation of the genetic alteration and exploratory analyses
• Eastern Cooperative Oncology Group (ECOG) of 0 or 1
• Measurable disease per RECIST 1.1
• Documented radiographic disease progression following at least one line of therapy in the advanced/metastatic setting

Exclusion Criteria:

• Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel
• Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with optimized anti-hypertensive therapy
• Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher than 5 mIU/mL while receiving appropriate thyroid hormone therapy
• Symptomatic and/or untreated central nervous system metastases
• Presence of another active cancer
• Ongoing adverse events from surgery or prior anti-cancer therapies, including radiation, targeted, or cytotoxic therapies
• Pregnant or breastfeeding women